Kevin N. Dalby

Last updated

Kevin N. Dalby is an American pharmacist, who is currently the Johnson & Johnson Centennial Professor at University of Texas at Austin. [1] [2] He examines fundamental mechanisms underlying human diseases to develop new treatments while also teaching and motivating students to conduct research.

Dalby is a member of several professional societies, including the American Society for Biochemistry and Molecular Biology, the American Chemical Society, and the American Association for Cancer Research.

In service to the country, Dalby serves on the National Institute of Health's study sections and is a peer reviewer for many leading journals.

Dalby's primary research goal is to discover and characterize fundamental mechanisms that regulate molecular signaling in cancer. As the Johnson & Johnson Centennial Professor of Chemical Biology & Medicinal Chemistry, he leads a team that uses a wide array of chemical, biochemical, biophysical, and physiological experiments to study phenomena of signal transduction.

His laboratory seeks to discover new cell signaling processes and develop new molecular tools to facilitate investigations. For 20 years, Dalby has led a laboratory that has studied protein kinase signaling, reporting several foundational studies about mechanisms of protein kinase regulation, substrate specificity, and inhibition in that time.

Related Research Articles

<span class="mw-page-title-main">Stuart Schreiber</span> American chemist

Stuart Schreiber, Ph.D. is the Morris Loeb Research Professor at Harvard University, a co-Founder of the Broad Institute, Howard Hughes Medical Institute Investigator, Emeritus, and a member of the National Academy of Sciences and National Academy of Medicine. His work integrates chemical biology and human biology to advance the science of therapeutics. Key advances include the discovery that small molecules can function as “molecular glues” that promote protein–protein interactions, the co-discovery of mTOR and its role in nutrient-response signaling, the discovery of histone deacetylases and the demonstration that chromatin marks regulate gene expression, the development and application of diversity-oriented synthesis to microbial therapeutics, and the discovery of vulnerabilities of cancer cells linked to genetic, lineage and cell-state features, including ferroptotic vulnerabilities. His notable awards include the Wolf Prize in Chemistry and the Arthur Cope Award. His approach to discovering new therapeutics guided many biotechnology companies that he founded, including Vertex Pharmaceuticals and Ariad Pharmaceuticals. He has founded or co-founded 14 biotechnology companies, which have developed 16 first-in-human approved drugs or advanced clinical candidates.

<span class="mw-page-title-main">John Kuriyan</span> American biochemist

John Kuriyan is the dean of basic sciences and a professor of biochemistry at Vanderbilt University School of Medicine. He was formerly the Chancellor's Professor at the University of California, Berkeley in the departments of molecular and cell biology (MCB) and chemistry, a faculty scientist in Berkeley Lab's physical biosciences division, and a Howard Hughes Medical Institute investigator. He is a member of the National Academy of Sciences and he has also been on the Life Sciences jury for the Infosys Prize in 2009, 2019 and 2020.

<span class="mw-page-title-main">Yasutomi Nishizuka</span> Japanese biochemist (1932–2004)

Yasutomi Nishizuka, MJA, ForMemRS was a prominent Japanese biochemist and made important contributions to the understanding of molecular mechanism of signal transduction across the cell membrane. In 1977, he discovered protein kinase C, which plays significant roles in a variety of intracellular signal transduction processes.

Kun-Liang Guan, is a Chinese and American biochemist. He won the MacArthur Award in 1998.

<span class="mw-page-title-main">JoAnne Stubbe</span> American chemist

JoAnne Stubbe is an American chemist best known for her work on ribonucleotide reductases, for which she was awarded the National Medal of Science in 2009. In 2017, she retired as a Professor of Chemistry and Biology at the Massachusetts Institute of Technology.

<span class="mw-page-title-main">Sidney Pestka</span>

Sidney Pestka was an American biochemist and geneticist. A recipient of the National Medal of Technology, he is sometimes referred to as the "father of interferon" for his groundbreaking work developing the interferons as treatments for major diseases such as hepatitis, multiple sclerosis, and cancer. Pestka was part of the team working on research involving the genetic code, protein synthesis and ribosome function that led to the 1968 Nobel Prize in Physiology or Medicine received by Marshall Warren Nirenberg.

Lewis C. Cantley is an American cell biologist and biochemist who has made significant advances to the understanding of cancer metabolism. Among his most notable contributions are the discovery and study of the enzyme PI-3-kinase, now known to be important to understanding cancer and diabetes mellitus. He is currently Meyer Director and Professor of Cancer Biology at the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine in New York City. He was formerly a professor in the Departments of Systems Biology and Medicine at Harvard Medical School, and the Director of Cancer Research at the Beth Israel Deaconess Medical Center, in Boston, Massachusetts. In 2016, he was elected Chairman of the Board for the Hope Funds for Cancer Research.

The NAS Award in Molecular Biology is awarded by the U.S. National Academy of Sciences "for recent notable discovery in molecular biology by a young scientist who is a citizen of the United States." It has been awarded annually since its inception in 1962.

<span class="mw-page-title-main">Laurence Pearl</span> British biologist

Laurence Harris Pearl FRS FMedSci is a British biochemist and structural biologist who is currently Professor of Structural Biology in the Genome Damage and Stability Centre and was Head of the School of Life Sciences at the University of Sussex.

Natalie G. Ahn is a professor of chemistry and biochemistry at the University of Colorado at Boulder. Her research is focused on understanding the mechanisms of cell signaling, with a speciality in phosphorylation and cancers. Ahn's work uses the tools of "classical chemistry" to work on understanding the genetic code and how genetics affects life processes. She has been a professor at the University of Colorado at Boulder since 2003, where she is a distinguished professor. She was a Howard Hughes Medical Institute investigator between 1994 and 2014. In 2018, she was elected to the National Academy of Sciences and named a fellow of the American Academy of Arts and Sciences.

<span class="mw-page-title-main">György Kéri</span>

György Kéri was a Hungarian biochemist, professor and Doctor of Biological Sciences (D.Sc.). His major field of research was signal transduction therapy and he participated in the development of novel drug discovery technologies and drug candidates that entered the clinical development process.

<span class="mw-page-title-main">Anthony R. Hunter</span> British-American biologist (born 1943)

Anthony Rex Hunter is a British-American biologist who is a professor of biology at the Salk Institute for Biological Studies and the University of California San Diego. His research publications list his name as Tony Hunter.

Craig M. Crews is an American scientist at Yale University known for his contributions to chemical biology. He is known for his contributions to the field of induced proximity through his work in creating heterobifunctional molecules that hijack cellular processes by inducing the interaction of two proteins inside a living cell. His initial work focused on the discovery of PROteolysis-TArgeting Chimeras (PROTACs) to trigger degradation of disease-causing proteins, a process known as targeted protein degradation (TPD), and he has since developed new versions of -TACs to leverage other cellular processes and protein families to treat disease.

<span class="mw-page-title-main">Mark A. Lemmon</span> English biochemist (born 1964)

Mark Andrew Lemmon an English-born biochemist, is the Alfred Gilman Professor and Department Chair of Pharmacology at Yale University where he also directs the Cancer Biology Institute.

<span class="mw-page-title-main">Richard Marais</span> Cancer researcher

Richard Malcolm Marais is Director of the Cancer Research UK (CRUK) Manchester Institute and Professor of Molecular Oncology at the University of Manchester.

<span class="mw-page-title-main">Carole LaBonne</span> Developmental and Stem Cell Biologist

Carole LaBonne is a Developmental and Stem Cell Biologist at Northwestern University. She is the Erastus O. Haven Professor of Life Sciences, and Chair of the Department of Molecular Biosciences.

Jin Zhang is a Chinese-American biochemist. She is a professor of pharmacology, chemistry and biochemistry, and biomedical engineering at the University of California, San Diego.

Barbara Imperiali is a Professor of Biology and Chemistry at Massachusetts Institute of Technology and Affiliate Member of the Broad Institute. She is an elected member of the National Academy of Sciences and a Fellow of the Royal Society of Chemistry.

<span class="mw-page-title-main">Alexandra Newton</span> US-based Protein Kinase C expert

Alexandra C. Newton is a Canadian and American biochemist. She is a Distinguished Professor of pharmacology at the University of California, San Diego. Newton runs a multidisciplinary Protein kinase C and Cell signaling biochemistry and cell biology research group in the School of Medicine, investigating molecular mechanisms of signal transduction in the Phospholipase C (PLC) and Phosphoinositide 3-kinase signaling pathways. She has been continuously funded by the US National Institutes of Health since 1988.

James Allen Wells is a Professor of Pharmaceutical Chemistry and Cellular & Molecular Pharmacology at the University of California, San Francisco (UCSF) and a member of the National Academy of Sciences. He received his B.A. degrees in biochemistry and psychology from University of California, Berkeley in 1973 and a PhD in biochemistry from Washington State University with Ralph Yount, PhD in 1979. He completed his postdoctoral studies at Stanford University School of Medicine with George Stark in 1982. He is a pioneer in protein engineering, phage display, fragment-based lead discovery, cellular apoptosis, and the cell surface proteome.

References

  1. "Kevin Dalby". utexas.edu. Retrieved December 13, 2016.
  2. "Faculty". utexas.edu. Retrieved December 13, 2016.